Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 12, 2023, titled "Zydus receivesfinal approval and 180 days shared exclusivity from the USFDA for Brexpiprazole Tablets".
Zydus Lifesciences Limited Press Release Jan 12 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Brexpiprazole Tablets, along with a period of shared exclusivity. The approval allows Zydus to market the drug in various dosages, which is indicated for treating major depressive disorder and schizophrenia. This approval marks a significant milestone as Zydus was among the first applicants to submit a complete application for this medication. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had substantial annual sales in the US market according to recent data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 10 2023
- Press Release Jan 06 2023
- Press Release Dec 30 2022
- Loss of Share Certificates
- Press Release Dec 22 2022
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jan 16 2023
- Press Release Jan 27 2023
- Press Release Feb 15 2023
- Zydus Lifesciences Limited Press Release Feb 17 2023
- Zydus Lifesciences Limited Press Release Feb 20 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences